← BOSTON SCIENTIFIC CORP
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $8.4b |
$9.0b
+7.89%
|
$9.8b
+8.57%
|
$10.7b
+9.28%
|
$9.9b
-7.66%
|
$11.9b
+19.92%
|
$12.7b
+6.68%
|
$14.2b
+12.29%
|
$16.7b
+17.61%
|
$20.1b
+19.87%
|
$21.0b
+4.59%
|
|
| Cost of Revenue | $2.4b |
$2.6b
+6.97%
|
$2.8b
+8.48%
|
$3.1b
+10.77%
|
$3.5b
+11.20%
|
$3.7b
+7.10%
|
$4.0b
+6.60%
|
$4.3b
+9.83%
|
$5.3b
+20.99%
|
$6.2b
+18.34%
|
$6.3b
+1.51%
|
|
| Cost of products sold (excluding amortization expense) | $2.4b |
$2.6b
+6.97%
|
$2.8b
+8.48%
|
$3.1b
+10.77%
|
$3.5b
+11.20%
|
$3.7b
+7.10%
|
$4.0b
+6.60%
|
$4.3b
+9.83%
|
$5.3b
+20.99%
|
$6.2b
+18.34%
|
— | |
| Gross Profit | $6.0b |
$6.5b
+8.27%
|
$7.0b
+8.61%
|
$7.6b
+8.69%
|
$6.4b
-15.38%
|
$8.2b
+26.81%
|
$8.7b
+6.73%
|
$9.9b
+13.40%
|
$11.5b
+16.11%
|
$13.9b
+20.57%
|
$14.7b
+5.97%
|
|
| Research and development expenses | $920.0m | $997.0m | $1.1b | $1.2b | $1.1b | $1.2b | $1.3b | $1.4b | $1.6b | $2.1b | $2.2b | |
| Selling, General and Administrative Expense | $3.1b | $3.3b | $3.6b | $3.9b | $3.8b | $4.4b | $4.5b | $5.2b | $6.0b | $6.9b | $7.2b | |
| Amortization of Intangible Assets | $545.0m | $565.0m | $599.0m | $699.0m | $789.0m | $741.0m | $803.0m | $828.0m | $856.0m | $897.0m | — | |
| Restructuring and Related Cost, Incurred Cost | $78.0m | $95.0m | — | — | — | — | — | — | — | — | — | |
| Restructuring net charges (credits) | $28.0m | $37.0m | $36.0m | $38.0m | $52.0m | $40.0m | $24.0m | $69.0m | $16.0m | $101.0m | — | |
| Operating Expenses | $5.5b | $5.2b | $5.5b | $6.1b | $6.5b | $7.0b | $7.1b | $7.6b | $8.9b | $10.2b | $10.3b | |
| Operating Income (Loss) | $447.0m |
$1.3b
+187.47%
|
$1.5b
+17.20%
|
$1.5b
+0.80%
|
($80.0m)
-105.27%
|
$1.2b
+1598.75%
|
$1.6b
+37.53%
|
$2.3b
+42.09%
|
$2.6b
+11.10%
|
$3.6b
+38.80%
|
$4.4b
+22.06%
|
|
| Other Operating Income (Expense), Net | $447.0m | $1.3b | $1.5b | $1.5b | ($362.0m) | ($218.0m) | $38.0m | $93.0m | $16.0m | $3.6b | $4.4b | |
| Interest Expense | $233.0m | $229.0m | $241.0m | $473.0m | $361.0m | $341.0m | $470.0m | $265.0m | $305.0m | $349.0m | $363.0m | |
| Foreign Currency Transaction Gain (Loss), before Tax | ($13.0m) | — | — | — | — | — | — | — | — | — | — | |
| Gain (Loss) on Investments | ($21.0m) | ($92.0m) | $155.0m | ($30.0m) | $398.0m | $250.0m | ($1.0m) | ($59.0m) | ($79.0m) | $139.0m | — | |
| Other Nonoperating Income (Expense) | ($37.0m) | ($124.0m) | $156.0m | ($358.0m) | $362.0m | $218.0m | ($38.0m) | ($93.0m) | ($321.0m) | ($228.0m) | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | ($1.0b) | ($408.0m) | $35.0m | ($1.1b) | ($660.0m) | ($648.0m) | ($1.1b) | ($394.0m) | ($261.0m) | ($311.0m) | $3.9b | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $177.0m | $933.0m | $1.4b | $687.0m | ($79.0m) | $1.1b | $1.1b | $2.0b | $2.3b | $3.4b | $3.9b | |
| Current Income Tax Expense (Benefit) | $173.0m | $584.0m | ($87.0m) | $275.0m | $87.0m | $178.0m | $451.0m | $320.0m | $526.0m | $505.0m | $193.0m | |
| Income Tax Expense (Benefit) | ($170.0m) | $828.0m | ($249.0m) | ($4.0b) | $2.0m | $36.0m | $443.0m | $393.0m | $436.0m | $493.0m | $193.0m | |
| Net Income (Loss) Available to Common Stockholders, Basic | $347.0m |
$104.0m
-70.03%
|
$1.7b
+1506.73%
|
$4.7b
+181.27%
|
($115.0m)
-102.45%
|
$985.0m
+956.52%
|
$642.0m
-34.82%
|
$1.6b
+144.55%
|
$1.9b
+18.03%
|
$2.9b
+56.40%
|
$3.7b
+26.78%
|
|
| Net Income (Loss) Attributable to Noncontrolling Interest | $0 | — | — | — | $73.0m | $0 | $0 | $1.0m | ($8.0m) | ($6.0m) | $3.7b | |
| Preferred stock dividends | — | — | $0 | $0 | $33.0m | $55.0m | $55.0m | $23.0m | $0 | $0 | — | |
| Earnings Per Share, Basic | $0.26 | $0.08 | $1.21 | $3.38 | ($0.08) | $0.69 | $0.45 | $1.08 | $1.26 | $1.96 | $2.49 | |
| Earnings Per Share, Diluted | $0.25 | $0.08 | $1.19 | $3.33 | ($0.08) | $0.69 | $0.45 | $1.07 | $1.25 | $1.94 | $2.47 | |
| Weighted Average Number of Shares Outstanding, Basic | 1.4b | 1.4b | 1.4b | 1.4b | 1.4b | 1.4b | 1.4b | 1.5b | 1.5b | 1.5b | 1.5b | |
| Weighted Average Number of Shares Outstanding, Diluted | 1.4b | 1.4b | 1.4b | 1.4b | 1.4b | 1.4b | 1.4b | 1.5b | 1.5b | 1.5b | 1.5b | |
| Additional Financial Items | ||||||||||||
| Amortization expense | $545.0m | $565.0m | $599.0m | $699.0m | $789.0m | $741.0m | $803.0m | $828.0m | $856.0m | $897.0m | — | |
| Contingent consideration net expense (benefit) | $29.0m | ($80.0m) | ($21.0m) | ($35.0m) | ($100.0m) | ($136.0m) | $35.0m | $58.0m | ($5.0m) | $18.0m | — | |
| Goodwill, Impairment Loss | $0 | — | — | — | $73.0m | $0 | $0 | $1.0m | ($8.0m) | ($6.0m) | $0 | |
| Intangible asset impairment charges | $11.0m | $4.0m | $35.0m | $105.0m | $460.0m | $370.0m | $132.0m | $58.0m | $386.0m | $46.0m | — | |
| Litigation-related net charges (credits) | $804.0m | $285.0m | $103.0m | $115.0m | $278.0m | $430.0m | $173.0m | ($111.0m) | $0 | $194.0m | — | |
| Other, net | ($37.0m) | ($124.0m) | $156.0m | ($358.0m) | $362.0m | $218.0m | ($38.0m) | ($93.0m) | ($16.0m) | $121.0m | — | |
| Royalty expense | $79.0m | $68.0m | $70.0m | $65.0m | $45.0m | $49.0m | $47.0m | $46.0m | $33.0m | $46.0m | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.